Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284849 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Phase 3 study of CRC, Colorectal Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT07284849 is a Phase 3 study of CRC, Colorectal Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 700 participants, above the 251-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT07284849, a Phase 3 study of CRC, Colorectal Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Placebo
- DRUG FOLFOX
- DRUG INCA33890
Study Locations (20)
Florida
- Florida Oncology & Hematology - Fort Myers
- University of Florida Health - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
- Advent Health - Orlando
- Orlando Health Cancer Institute Downtown Orlando - Orlando
- Ascension Sacred Heart Pensacola - Pensacola
- Tampa General Hospital-Cancer Institute - Tampa
California
- Toi Clinical Research - Cerritos
- Los Angeles Cancer Network - Fountain Valley
- Providence Medical Foundation - Fullerton
- Long Beach Medical Center - Long Beach
- University of California Los Angeles Health - Los Angeles
Arizona
- The University of Arizona Cancer Center - Tucson
- Roche Tissue Diagnostics, Companion Diagnostics - Tucson
Georgia
- Piedmont Cancer Institute - Locust Grove
- Northwest Georgia Oncology Centers - Marietta
Colorado
- Sarah Cannon Research Institute Scri Oncology Partners - Aurora
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- George Washington University - Washington D.C.
Hawaii
- University of Hawaii Cancer Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2029-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284849
The ClinicalTrials.gov registry entry for NCT07284849 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 251-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (179% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CRC, Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07284849 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07284849 about?
NCT07284849 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer". The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
What is the current status of trial NCT07284849?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2026-03-05. Estimated completion is 2029-09-28.
What conditions does trial NCT07284849 study?
This clinical trial studies the following conditions: CRC, Colorectal Cancer.
What interventions are being tested in trial NCT07284849?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (DRUG), FOLFOX (DRUG), INCA33890 (DRUG).
Who is sponsoring clinical trial NCT07284849?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284849 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CRC, Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
RECRUITING · NA
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
RECRUITING
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.